Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo

British Journal of Cancer

Volumn 86, Issue 5, 2002, Pages 796-802

  Van Valckenborgh, E ^a   De Raeve, H ^b   Devy, L ^c   Blacher, S ^c   Munaut, C ^c   Noel A ^c   Van Marck, E ^b   Van Riet, I ^a   Van Camp, B ^a   Vanderkerken, Karin ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Angiogenesis; Multiple myeloma; MVD; Rat aortic ring assay

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MOUSE; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE CULTURE; VASCULAR RING;

ANIMALS; AORTA; BIOLOGICAL ASSAY; CELL COMMUNICATION; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; MICROCIRCULATION; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE;

EID: 18344376170     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600137     Document Type: Article

References (41)

1. The 5TMM series: A useful in vivo mouse model of human multiple myeloma
2. Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells
3. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation
4. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
5. The thin red line: Angiogenesis in normal and malignant hematopoiesis
6. Improved quantification of angiogenesis in the rat aortic ring assay
7. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin
8. Vascular endothelial growth factor: Regulation by cell differentiation and activated second messenger pathways
9. Recent advances in research on multistage tumorigenesis
10. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
11. Thalidomide is an inhibitor of angiogenesis
12. Vascular endothelial growth factor and interleukin-6 in paracrine tumor- stromal cell interactions in multiple myeloma
13. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
14. Molecular and biological properties of vascular endothelial growth factor
15. Role of vascular endothelial growth factor in the regulation of angiogenesis
16. Angiogenesis in cancer, vascular, rheumatoid and other disease
17. Angiogenesis
18. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: Effect on in vivo mammary tumor growth and angiogenesis
19. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells
20. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
21. Increased vascularization in myeloma
22. Angiogenesis and angiogenic mediators in haematological malignancies
23. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices
24. The regulation of neovascularization of matrix metalloproteinases and their inhibitors
25. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro
26. Idiopathic paraproteinemia. II. Transplantation of the paraprotein- producing clone from old to young C57BL/KaLwRij mice
27. Animal model of human disease. Multiple myeloma
28. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma
29. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences
30. Antitumor activity of thalidomide in refractory multiple myeloma
31. Current status of antiangiogenic factors
32. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia
33. Bone marrow angiogenesis and progression in multiple myeloma
34. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis
35. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
36. Follow-up of bone lesions in an experimental multiple myeloma mouse model: Description of an in vivo technique using radiography dedicated for mammography
37. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse
38. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells
39. Bone marrow microenvironmental-induced upregulation of MMP-9 activity in murine multiple myeloma cells
40. Expression of the angiogenesis-inducing molecules VEGF and bFGF in multiple myeloma and its regulation by paracrine interactions between tumor cells and stromal bone marrow cells
41. Angiogenesis and tumor metastasis